

## Therapy decision tree—Crohn's disease

---

### Objective

Provide direction regarding the choice of therapy for patients with Crohn's disease

### Patient Population

Adult patients ( $\geq 18$  years) with a known diagnosis of Crohn's disease

### Highlight Box

Therapy decisions are based on anatomic location of disease, severity of disease, disease complications, extra-intestinal manifestations of the disease, other comorbidities, and patient preference. Treatment goals include induction and maintenance of remission.

New therapies are constantly being developed and should be considered.

### Introduction

Crohn's disease (CD) is a chronic inflammatory condition that affects any portion of the gastrointestinal tract from the mouth to the anus and perianal region. Extra-intestinal manifestations and/or complications can occur. The most commonly affected parts of the GI tract are the terminal ileum and colon. Inflammation is typically segmental, asymmetrical and transmural. Most patients are diagnosed with an inflammatory phenotype at first presentation, but over time, complications such as strictures, fistulas or abscesses can develop in over half of patients. These complications often require surgery.

### Types of Crohn's Disease



Ileal



Colonic



Proximal Small Bowel

# crohn's colitis



Perianal



Gastroduodenal

Images used with permission from IBD Unit ©IBD Unit. All rights reserved

The Montreal classification is commonly used to classify the major phenotypic features of CD based on age at diagnosis, location of the disease and disease behavior.

Clinical factors	Montreal Classification
Age at diagnosis (A)	A1: 16 years or younger A2: 17-40 years A3: Over 40 years
Disease Location (L)	L1: Terminal ileum L2: Colonic L3: Ileocolonic L4: Upper GI*
Disease Behavior (B)	B1**: Nonstricturing, nonpenetrating B2: stricturing B3: penetrating p***: perianal disease modifier

\*L4 is a modifier that can be added to L1-3 when concomitant upper GI disease is present

\*\*B1 category should be considered 'interim' until a pre-specified time has elapsed from the time of diagnosis. Such a time period may vary from study to study (e.g. 5-10 years is suggested) but should be defined in order for B1 behavior to be considered 'definitive.' GI—Gastrointestinal

\*\*\*p is a modifier that can be added to B1-3 when concomitant perianal disease is present

Prior to therapy decisions, the following assessments should be carried out and treatment goals discussed with the patient.

**Goal of therapy:** deep and prolonged remission with long-term goal of preventing complications and halting the progressive course of the disease. Deep remission is a combination of symptomatic and objective markers of remission.

## Assess the inflammatory status of the disease: A

- Symptoms: Fever, abdominal pain, diarrhea, GI bleeding, localized tenderness, weight loss and symptoms of extra-intestinal manifestations of IBD.
- Clinical laboratory testing: Complete blood count (CBC), C-reactive protein (CRP), Fecal calprotectin (FCP)
- Imaging: Endoscopy and Computed Tomography (CT)-Enterography OR Magnetic resonance enterography OR intestinal ultrasound

## Assess comorbidities as well as disease and therapy-related complications: B

1. Infections such as *C. difficile*, cytomegalovirus (CMV)
2. Stricture/remodeling: Abnormal imaging (bowel dilation), obstructive symptoms, stricture on endoscopy
3. Symptoms related to prior surgery: Bile acid diarrhea, Bacterial overgrowth, Steatorrhea/fat malabsorption.
4. Previous IBD medication history
5. Perianal or abdominal abscess or fistula: Pain, fistula drainage, fever (see Perianal Crohn's protocol)
6. Immune mediated inflammatory conditions: Ankylosing spondylitis, arthritis, psoriasis, pyoderma gangrenosum, uveitis, etc.
7. History of malignancies

## Predicted severity of disease course: C

### Moderate/High risk:


1. Active smoking
2. Recurrent hospitalizations
3. Perianal disease, stricturing/penetrating disease
4. >1 bowel resection
5. Length of affected bowel (ileocolonic and/or small bowel involvement beyond T1)
6. Diagnosis at a younger age (<40 years)

**The absence of the above-mentioned factors are indicative of low risk.**

# crohn's colitis


## Management of mild Crohn's disease

Mild disease defined as CDAI <220 or HBI ≤7. Following complete evaluation with endoscopy (ileocolonoscopy +/- upper endoscopy) and/or imaging (enterography, capsule endoscopy, and/or intestinal ultrasound), and lab tests, the choice of treatment will in part depend on the distribution of disease as well as disease activity.



\*Topical steroids includes steroids such as budesonide

# crohn's colitis



Instruct the patient to contact the office if new symptoms occur

\* Consider early ileal resection (especially in localized ileo- cecal disease and stricturing disease)

\*\*Ongoing use of steroids is not recommended; do not prescribe more than 2 courses of steroids over 12 months

## Other Resources

### For IBD Providers

Inflammatory Bowel Disease: [Drug Comparison chart](#)

### For Patients

[Crohn's and Colitis Canada: IBD journey webpage](#)

UpToDate® - Patient education: Crohn's disease (Beyond the Basics) (freely accessible)

[https://www.uptodate.com/contents/crohn-disease-beyond-the-basics?search=crohns%20disease&source=search\\_result&selectedTitle=1~20&usage\\_type=default&display\\_rank=1](https://www.uptodate.com/contents/crohn-disease-beyond-the-basics?search=crohns%20disease&source=search_result&selectedTitle=1~20&usage_type=default&display_rank=1)

## References

Nguyen et al. Positioning Therapies in the Management of Crohn's Disease. Clin Gastroenterol and Hepatol 2020; 18(6):1268-79 <https://doi.org/10.1016/j.cgh.2019.10.035>

Panaccione et al. Canadian Association of Gastroenterology Clinical Practice Guidelines for the Management of Luminal Crohn's Disease. J Can Assoc Gastroenterol 2019; 2(3): e1-e34 <https://doi.org/10.1093/jcag/gwz019>

Lichtensein et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterology 2018; 113:481-517 <https://doi.org/10.1038/ajg.2018.27>

Sandborn W.J. Evaluation and Treatment: Clinical Decision Tool Gastroenterology 2014; 147:702-705 <https://doi.org/10.1053/j.gastro.2014.07.022>

Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. *Gastroenterology*. 2021;160(5):1570-1583. <https://doi.org/10.1053/j.gastro.2020.12.031>

2024 ECCO guidelines (expected Jan 2024)